Towards a muscarinic hypothesis of schizophrenia

被引：211
作者：
Raedler, T. J.
Bymaster, F. P.
Tandon, R.
Copolov, D.
Dean, B.
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Psychiat, D-20246 Hamburg, Germany
[2] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA
[3] State Florida, Dept Mental Hlth, Tallahassee, FL USA
[4] Mental Hlth Res Inst, Parkville, Vic, Australia
[5] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia
[6] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia
[7] Monash Univ, Dept Med Psychol, Clayton, Vic 3168, Australia
来源：
MOLECULAR PSYCHIATRY | 2007年 / 12卷 / 03期
关键词：
schizophrenia; acetylcholine; receptors; muscarinic; muscarinic agonists; muscarinic antagonists; etiology;
D O I：
10.1038/sj.mp.4001924
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Although the neurotransmitter dopamine plays a prominent role in the pathogenesis and treatment of schizophrenia, the dopamine hypothesis of schizophrenia fails to explain all aspects of this disorder. It is increasingly evident that the pathology of schizophrenia also involves other neurotransmitter systems. Data from many streams of research including preclinical and clinical pharmacology, treatment studies, post-mortem studies and neuroimaging suggest an important role for the muscarinic cholinergic system in the pathophysiology of schizophrenia. This review will focus on evidence that supports the hypothesis that the muscarinic system is involved in the pathogenesis of schizophrenia and that muscarinic receptors may represent promising novel targets for the treatment of this disorder.
引用
收藏
页码：232 / 246
页数：15
相关论文
共 201 条
  • [21] Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
    Breier, A
    Su, TP
    Saunders, R
    Carson, RE
    Kolachana, BS
    de Bartolomeis, A
    Weinberger, DR
    Weisenfeld, N
    Malhotra, AK
    Eckelman, WC
    Pickar, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) : 2569 - 2574
  • [22] An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia
    Buchanan, RW
    Summerfelt, A
    Tek, C
    Gold, J
    [J]. SCHIZOPHRENIA RESEARCH, 2003, 59 (01) : 29 - 33
  • [23] BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469
  • [24] BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646
  • [25] BURSTEIN FS, 2005, J PHARMACOL EXP THER, V15, P1272
  • [26] BYBMASTER FP, 2003, NEUROCHEM RES, V28, P437
  • [27] Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1,-adrenergic receptors in vitro
    Bymaster, FP
    Nelson, DL
    DeLapp, NW
    Falcone, JF
    Eckols, K
    Truex, LL
    Foreman, MM
    Lucaites, VL
    Calligaro, DO
    [J]. SCHIZOPHRENIA RESEARCH, 1999, 37 (01) : 107 - 122
  • [28] Radioreceptor binding profile of the atypical antipsychotic olanzapine
    Bymaster, FP
    Calligaro, DO
    Falcone, JF
    Marsh, RD
    Moore, NA
    Tye, NC
    Seeman, P
    Wong, DT
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) : 87 - 96
  • [29] Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity
    Bymaster, FP
    Carter, PA
    Yamada, M
    Gomeza, J
    Wess, J
    Hamilton, SE
    Nathanson, NM
    McKinzie, DL
    Felder, CC
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 17 (07) : 1403 - 1410
  • [30] Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane
    Bymaster, FP
    Shannon, HE
    Rasmussen, K
    Delapp, NW
    Mitch, CH
    Ward, JS
    Calligaro, DO
    Ludvigsen, TS
    Sheardown, MJ
    Olesen, PH
    Swedberg, MDB
    Sauerberg, P
    Fink-Jensen, A
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 356 (2-3) : 109 - 119
12345678910